Surgery Today

, Volume 44, Issue 9, pp 1678–1684 | Cite as

A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer

  • Kimihiro Tanaka
  • Eriko TokunagaEmail author
  • Nami Yamashita
  • Kenji Taketani
  • Sayuri Akiyoshi
  • Masaru Morita
  • Yoshihiko Maehara
Original Article



The aim of the current study was to explore the efficacy and safety of combination therapy using a luteinizing hormone-releasing hormone (LHRH) agonist plus an aromatase inhibitor (AI) as second-line therapy in premenopausal females with hormone receptor (HR)-positive recurrent or metastatic breast cancer (MBC).


A retrospective analysis was conducted in patients registered in the breast cancer database of our institution between January 2001 and December 2012. The breast cancer database identified 14 premenopausal patients who had been treated with an LHRH agonist plus AI for HR-positive recurrent or MBC.


Fourteen patients with recurrent breast cancer (N = 10) or metastatic disease at primary diagnosis (N = 4) were included in the present study. All patients had previously been treated with an LHRH agonist plus tamoxifen. The clinical benefit rate was 71.4 % and the median TTP was 11 months (95 % confidence interval 1.7–20.3 months). One patient discontinued treatment because of liver dysfunction (grade 3).


The combination of an LHRH agonist plus an AI is a treatment option for premenopausal females with HR-positive MBC that can prolong the chemotherapy-free interval and yield effective disease stabilization.


Luteinizing hormone-releasing hormone agonist Aromatase inhibitor Premenopausal Hormone receptor-positive Metastatic breast cancer 


Conflict of interest

The authors have no conflicts of interest to declare.


  1. 1.
    Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005;104:1742–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100:44–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Beatson GT. On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896;148:162–5.CrossRefGoogle Scholar
  4. 4.
    Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998;16:994–9.PubMedGoogle Scholar
  5. 5.
    Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19:343–53.PubMedGoogle Scholar
  6. 6.
    Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92:2247–58.PubMedCrossRefGoogle Scholar
  8. 8.
    Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003;14:1391–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Sinha S, Kaseta J, Santner SJ, Demers LM, Bremmer WJ, Santen RJ. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. Breast Cancer Res Treat. 1998;48:45–51.PubMedCrossRefGoogle Scholar
  10. 10.
    Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679–91.PubMedCrossRefGoogle Scholar
  11. 11.
    Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012;13:345–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer. 2004;90:590–4.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Cheung KL, Agrawal A, Folkerd E, Dowsett M, Robertson JF, Winterbottom L. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Eur J Cancer. 2010;46:2936–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol. 2010;28:3917–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Yao S, Xu B, Li Q, Zhang P, Yuan P, Wang J, et al. Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer. Endocr J. 2011;58:509–16.PubMedCrossRefGoogle Scholar
  16. 16.
    Nishimura R, Anan K, Yamamoto Y, Higaki K, Tanaka M, Shibuta K, et al. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. Oncol Rep. 2013;29:1707–13.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRefGoogle Scholar
  18. 18.
    National Cancer Institute (2013) Common terminology criteria for adverse events (CTCAE) v4.0.
  19. 19.
    Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, et al. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer. 2012;48:1932–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA. 1990;87:6883–7.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Kimihiro Tanaka
    • 1
  • Eriko Tokunaga
    • 1
    • 2
    Email author
  • Nami Yamashita
    • 1
  • Kenji Taketani
    • 1
  • Sayuri Akiyoshi
    • 1
  • Masaru Morita
    • 1
  • Yoshihiko Maehara
    • 1
  1. 1.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityHigashi-kuJapan
  2. 2.Department of Comprehensive Clinical Oncology, Faculty of Medical SciencesKyushu UniversityHigashi-kuJapan

Personalised recommendations